Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price traded up 4.1% on Wednesday . The company traded as high as $105.77 and last traded at $104.40. 18,274 shares were traded during mid-day trading, a decline of 87% from the average session volume of 139,152 shares. The stock had previously closed at $100.27.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PVLA. BTIG Research raised their target price on shares of Palvella Therapeutics from $167.00 to $192.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Canaccord Genuity Group raised their price objective on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Stifel Nicolaus boosted their target price on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Craig Hallum began coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 target price for the company. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $155.60.

Palvella Therapeutics Stock Performance

The stock’s 50-day moving average price is $88.24 and its 200-day moving average price is $59.42. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -40.24 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds have recently added to or reduced their stakes in PVLA. Suvretta Capital Management LLC raised its position in Palvella Therapeutics by 15.1% during the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after acquiring an additional 107,937 shares during the last quarter. Frazier Life Sciences Management L.P. increased its stake in shares of Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after purchasing an additional 32,388 shares in the last quarter. First Light Asset Management LLC acquired a new position in shares of Palvella Therapeutics during the 3rd quarter worth approximately $33,949,000. Vanguard Group Inc. lifted its stake in Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after buying an additional 330,847 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at $21,255,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.